| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
This compound targets cereblon (CRBN), a component of the E3 ubiquitin ligase complex; the pomalidomide moiety binds to CRBN, recruiting the E3 ligase to ubiquitinate and degrade target proteins when conjugated to a suitable warhead via the PEG1-NH₂ linker.
|
|---|---|
| ln Vitro |
In vitro, Pomalidomide-PEG1-NH₂ hydrochloride is used as a building block for synthesizing PROTAC molecules; the amine group enables conjugation to target protein ligands; the resulting PROTACs induce ubiquitination and proteasomal degradation of target proteins in cell-based assays.
|
| ln Vivo |
In vivo, PROTACs synthesized using Pomalidomide-PEG1-NH₂ hydrochloride have demonstrated efficacy in degrading target proteins in animal models; the pomalidomide moiety provides CRBN-mediated degradation; the PEG linker improves solubility and bioavailability.
|
| Enzyme Assay |
Non-cellular binding assay: The binding affinity of Pomalidomide-PEG1-NH₂ hydrochloride to cereblon (CRBN) is assessed by surface plasmon resonance (SPR) or fluorescence polarization using recombinant CRBN-DDB1 protein complexes; competition assays with labeled pomalidomide are performed to determine IC₅₀ and binding kinetics.
|
| Cell Assay |
Cellular assays: Cells expressing a target protein of interest are treated with PROTACs synthesized from Pomalidomide-PEG1-NH₂ hydrochloride; target protein degradation is assessed by Western blotting at various time points and concentrations; cell viability and proliferation are evaluated by MTT or CellTiter-Glo assays; the ubiquitination status of the target protein is assessed by immunoprecipitation.
|
| Animal Protocol |
In vivo animal experiments: PROTACs synthesized from Pomalidomide-PEG1-NH₂ hydrochloride are administered to tumor-bearing mice via intravenous or intraperitoneal injection; target protein degradation in tumor tissues is confirmed by Western blotting; tumor growth inhibition, body weight changes, and organ toxicity are monitored; pharmacokinetic parameters are determined from plasma samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Pomalidomide-PEG1-NH₂ hydrochloride is a linker intermediate; the pharmacokinetics of the final PROTAC molecule depend on the target ligand and overall properties; the PEG spacer improves aqueous solubility and may reduce clearance; the compound is typically used in early-stage research.
|
| Toxicity/Toxicokinetics |
Toxicological profile: Pomalidomide-PEG1-NH₂ hydrochloride is a research chemical with limited toxicological data; pomalidomide is known to have teratogenic effects and should be handled with extreme care; standard safety precautions for handling potent E3 ligase ligands apply.
|
| References | |
| Additional Infomation |
Other information: Pomalidomide-PEG1-NH₂ hydrochloride is used in PROTAC research for targeted protein degradation; the amine group (NH₂) allows conjugation to carboxyl groups, isocyanates, or activated esters; the hydrochloride salt form improves solubility and stability.
|
| Molecular Formula |
C17H19CLN4O6
|
|---|---|
| Molecular Weight |
410.808963060379
|
| Exact Mass |
410.099
|
| CAS # |
2380273-67-4
|
| PubChem CID |
139035683
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
666
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.O=C1C(CCC(N1)=O)N1C(C2C=CC=C(C=2C1=O)NC(COCCN)=O)=O
|
| InChi Key |
QADSMEPQGOSRMU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18N4O6.ClH/c18-6-7-27-8-13(23)19-10-3-1-2-9-14(10)17(26)21(16(9)25)11-4-5-12(22)20-15(11)24;/h1-3,11H,4-8,18H2,(H,19,23)(H,20,22,24);1H
|
| Chemical Name |
2-(2-aminoethoxy)-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]acetamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~62.5 mg/mL (~152.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4342 mL | 12.1711 mL | 24.3422 mL | |
| 5 mM | 0.4868 mL | 2.4342 mL | 4.8684 mL | |
| 10 mM | 0.2434 mL | 1.2171 mL | 2.4342 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
